Previous studies have found that NEDD9 can activate the AKT/mTOR pathway and affect tumor progression, but no relevant studies have been reported in HCC (Izumchenko et al. 2009; Xue et al. 2020). This evidence concerns the gene AKT1 and hepatocellular carcinoma.